To amend the Controlled Substances Act to better align such Act with modern medical knowledge, establish a new system for the scheduling of controlled substances, redelegate certain authorities, promote scientific research, and for other purposes.
Key claim: A newly introduced House bill would rewrite how the federal government classifies controlled drugs, shift some scheduling powers, and make scientific research on those substances easier; it has been sent to several House committees and is not yet law.
Abstract
(HR10923 · 119th Congress) Latest action (2026-10-29): Referred to the Committee on Energy and Commerce, and in addition to the Committees on the Judiciary, Oversight and Government Reform, Natural Resources, Agriculture, and Transportation and Infrastructure, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
Why this matters
Federal drug scheduling is one of the biggest regulatory frictions on biomedical research into psychedelics, cannabinoids, and other Schedule I substances, where DEA registration and sourcing requirements can add years to a study. A statutory rewrite that redistributes scheduling authority and explicitly facilitates research would change which agencies gate access and how quickly new evidence can move a substance between schedules. At the introduced-bill stage this signals congressional appetite rather than a change in rules researchers face today.